NCT02142855

Brief Summary

The first goal of this study is the follow young and older people over a period of 8 weeks to define the processes responsible for loss of muscle length and width in age-related muscle wasting (sarcopenia) and allow us to look at age-related differences in tendon. Secondly, we will assess two different exercise interventions for reversing human sarcopenia; one which involves shortening of the muscle and the other which involves lengthening, whilst also studying why these exercises work the way they do. This project will have significant implications for our understanding of the control of skeletal muscle and tendon size in humans, particularly in relation to sarcopenia and the surrounding health issues.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started May 2014

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

May 16, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 20, 2014

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

October 30, 2017

Status Verified

October 1, 2017

Enrollment Period

3 years

First QC Date

May 16, 2014

Last Update Submit

October 27, 2017

Conditions

Healthy

Keywords

volunteersyoung (18-30 y)older (65-75 y)age groups

Outcome Measures

Primary Outcomes (1)

  • Muscle protein synthesis

    Comparison of muscle protein synthesis using D2O in young and older individuals and in response to 8 weeks concentric or eccentric exercise training

    0 - 8 weeks

Secondary Outcomes (1)

  • Tendon protein synthesis

    0 - 8 weeks

Other Outcomes (1)

  • Muscle function

    0 - 8 weeks

Study Arms (6)

Old Control

NO INTERVENTION

Older individuals (65-75 y) with no exercise intervention

Old Concentric

EXPERIMENTAL

Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training

Behavioral: Concentric Exercise Training

Old Eccentric

EXPERIMENTAL

Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training

Behavioral: Eccentric Exercise Training

Young Control

NO INTERVENTION

Young individuals (18-30 y) with no exercise intervention

Young Concentric

EXPERIMENTAL

Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training

Behavioral: Concentric Exercise Training

Young Eccentric

EXPERIMENTAL

Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training

Behavioral: Eccentric Exercise Training

Interventions

Concentric Exercise TrainingBEHAVIORAL

8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets

Old ConcentricYoung Concentric
Eccentric Exercise TrainingBEHAVIORAL

8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets

Old EccentricYoung Eccentric

Eligibility Criteria

Age18 Years - 75 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy male volunteers
  • Body mass index 18-30 kg/m2
  • Aged 18-35 and 65-75 years

You may not qualify if:

  • Participation in a formal exercise regime,
  • A BMI \< 18 or \> 30 kg/m2,
  • Active cardiovascular disease,
  • Taking beta-adrenergic blocking agents, statins or non-steroidal anti-inflammatory drugs,
  • Cerebrovascular disease,
  • Respiratory disease,
  • Metabolic disease,
  • Active inflammatory bowel or renal disease,
  • Malignancy,
  • Recent steroid treatment (within 6 months) or hormone replacement therapy,
  • Clotting dysfunction,
  • Musculoskeletal or neurological disorders,
  • Family history of early (\<55y) death from cardiovascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nottingham

Derby, Derbyshire, DE22 3DT, United Kingdom

Location

Study Officials

  • Marco V Narici, PhD

    University of Nottingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2014

First Posted

May 20, 2014

Study Start

May 1, 2014

Primary Completion

May 1, 2017

Study Completion

May 1, 2017

Last Updated

October 30, 2017

Record last verified: 2017-10

Locations

GB(1)